Clinical Trials Sponsored by Ardena

Total 801 results

Arena Pharmaceuticals

Terminated

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) (CAPTIVATE)

Irritable Bowel Syndrome

United States
Arena Pharmaceuticals

Completed

A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers

Healthy

United States
Arena Pharmaceuticals

Terminated

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Pyoderma Gangrenosum

Australia, New Zealand
Arena Pharmaceuticals

Completed

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, New Zealand, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Arena Pharmaceuticals

Completed

A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation

Smoking Cessation

United States
Arena Pharmaceuticals

Completed

Single-dose Safety Study of APD916 in Healthy Volunteers

Narcolepsy With or Without Cataplexy

United States
Arena Pharmaceuticals

Completed

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Korea, Republic of, Latvia, Lithuania, New Zealand, Poland, Romania, Russian Federation, Spain, Ukraine, United Kingdom
Arena Pharmaceuticals

Terminated

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Arena Pharmaceuticals

Completed

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

Primary Insomnia

United States
Arena Pharmaceuticals

Completed

Safety and Efficacy Study of APD125 in Patient With Insomnia

Insomnia

United States
Arena Pharmaceuticals

Completed

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis (ELEVATE UC 12)

Ulcerative Colitis

United States, Spain, Israel, Netherlands, Australia, Korea, Republic of, Czechia, Italy, Russian Federation, Croatia, Portugal, Serbia, Belarus, Canada, Georgia, Hungary, Ukraine, Germany, Poland, Belgium, Turkey, Japan, Thailand, India and more
Arena Pharmaceuticals

Completed

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC 52)

Ulcerative Colitis

Israel, Spain, United States, Australia, Denmark, Korea, Republic of, Czechia, Russian Federation, Croatia, Portugal, Serbia, Taiwan, Canada, Bulgaria, Belarus, Georgia, Hungary, Italy, Latvia, Netherlands, Ukraine, Germany, Poland, B... and more
Arena Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (ADVISE)

Atopic Dermatitis

United States, Australia, Canada
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Arena Pharmaceuticals

Completed

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Abdominal Pain | Crohn's Disease

United States
Arena Pharmaceuticals

Terminated

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Inflammatory Bowel Diseases | Skin Extra-intestinal Manifestations

Belgium, Germany, Serbia
Arena Pharmaceuticals

Completed

Single-Dose Safety Study of APD791 in Healthy Volunteers

Healthy

United States
Ardana Bioscience Ltd

Completed

Study of 3 Doses of ARD-0403 in Testosterone Deficient Men (ARD-0403-001)

Hypogonadism

Belarus
Ardana Bioscience Ltd

Completed

Open-Label Study of ARD-0403 in Testosterone Deficient Men

Hypogonadism

United States
Ardana Bioscience Ltd

Terminated

Open-Label Study of ARD-0403 in Testosterone Deficient Men (ARD-0403-010)

Hypogonadism

United States
Ardea Biosciences, Inc.

Completed

RDEA3170 Tablet and Capsule Bioavailability Study

Healthy

United States
Ardea Biosciences, Inc.

Completed

Lesinurad and Febuxostat Combination Extension Study in Gout

Gout

United States, Canada, Australia, New Zealand, Switzerland, Poland
Ardea Biosciences, Inc.

Completed

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Gout

United States
Ardea Biosciences, Inc.

Completed

RDEA3170 and Febuxostat Combination Study in Gout Subjects

Gout

United States
Ardea Biosciences, Inc.

Completed

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Healthy

United States
Ardea Biosciences, Inc.

Completed

RDEA3170 PK/PD Study

Gout

United States
Ardea Biosciences, Inc.

Completed

RDEA3170 Monotherapy in Subjects With Gout

Gout

United States
Ardea Biosciences, Inc.

Completed

Lesinurad Tablet Relative Bioavailability

Healthy

United States
Ardea Biosciences, Inc.

Completed

Gout Dose Response Study

Hyperuricemia

Poland, United States, Canada, Bulgaria, Germany, Georgia, Czech Republic
Ardea Biosciences, Inc.

Completed

Lesinurad Interaction Study With Ranitidine

Healthy

United States
Ardea Biosciences, Inc.

Completed

NSAID Drug Interaction Study

Gout

United States
argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Thyroid Eye Disease

United States
argenx

Not yet recruiting

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Myasthenia Gravis
argenx

Recruiting

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Multifocal Motor Neuropathy

United States, Italy, Bulgaria, Latvia, Czechia, Poland, China, Serbia, Sweden
argenx

Recruiting

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Healthy Volunteers

Netherlands
argenx

Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

United States, Germany, Spain, Korea, Republic of, Austria, Turkey, Lithuania, Australia, Thailand, Serbia, Poland, Italy, France, Netherlands, Argentina, United Kingdom, Georgia, Belgium, Bulgaria, Canada, Cyprus, Denmark, Greece, Hu... and more
argenx

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United Kingdom, Spain, United States, Austria, Germany, Belgium, Italy, Netherlands, France, Georgia, Poland, Canada
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
argenx

Terminated

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS+)

Pemphigus Vulgaris | Pemphigus Foliaceus

United States, Germany, Italy, Australia, Bulgaria, China, France, Georgia, Greece, Hungary, India, Israel, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
argenx

Completed

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Bioequivalence

United States
argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
argenx

Completed

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia
argenx

Completed

SAD and MAD Study With IV and SC Doses of ARGX-117 (ARGX-117)

Healthy Volunteers

Netherlands
argenx

Approved for marketing

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States
argenx

Completed

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Healthy Volunteers

Netherlands
argenx

Completed

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Healthy Volunteers
Ardea Biosciences, Inc.

Completed

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Gout

Brazil
Ardea Biosciences, Inc.

Completed

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Gout

United States

Clinical Trials Sponsored by Ardena

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations